Key facts
- EpiPaws’s last known valuation is $1.3M (Dec 2024).
- It has raised $420K; the latest was Angel (individual) ($140K) in Aug 2025.
- Notable investors include Plug and Play Tech Center, MedTech Innovator, BioTools Innovator, Fau Tech Runway, Kevin O'Leary — 7 tracked in total.
- EpiPaws has filed 1 Form D with the SEC, most recently Aug 2025 ($145K sold to 5 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for EpiPaws
- ·The full record, as it builds
Funding rounds
No funding rounds for EpiPaws are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EpiPaws
Developer of epigenetic biomarkers intended to promote proactive pet healthcare. The company offers biomarker tests to improve pet healthcare and increase pet longevity through better biomarkers, optimizing diets, and the development of nutraceuticals that help keep pets happy and healthy, enabling pet owners to learn how to feed, exercise, and monitor the health of a dog or cat.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Fort Lauderdale, FL, United States
- Founded
- 2022
- Employees
- 7
- Website
- epipaws.com/
- Ownership
- Privately Held (backing)
EpiPaws doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EpiPaws shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EpiPaws in its N-PORT filings yet. We sweep new filings monthly.